Specific alterations in gut microbiota in patients with chronic kidney disease: an updated systematic review

Jin, Zhao; Ning, Xiaoxuan; Liu, Baojian; Dong, Ran; Bai, Ming; Sun, Shiren

doi:10.1080/0886022x.2020.1864404

Cited by 81 publications

(70 citation statements)

References 74 publications

(258 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Noteworthy, CKD patients followed specific nutritional advice, whereas the CTRL group was on a free diet. A recent systematic review investigated the alteration of gut microbiota in CKD compared to healthy subjects [ 65 ]: only 33.3% of the studies showed higher richness in CKD subjects, among which we found an Italian study that reported our same result [ 66 ].…”

Section: Discussionmentioning

confidence: 79%

Curcumin Supplementation (Meriva®) Modulates Inflammation, Lipid Peroxidation and Gut Microbiota Composition in Chronic Kidney Disease

et al. 2022

View full text Add to dashboard Cite

Chronic kidney disease (CKD) subjects suffer from high risk of cardiovascular mortality, and any intervention preventing the progression of CKD may have an enormous impact on public health. In the last decade, there has been growing awareness that the gut microbiota (GM) can play a pivotal role in controlling the pathogenesis of systemic inflammatory state and CKD progression. To ameliorate the quality of life in CKD subjects, the use of dietary supplements has increased over time. Among those, curcumin has demonstrated significant in vitro anti-inflammatory properties. In this pilot study, 24 CKD patients and 20 healthy volunteers were recruited. CKD patients followed nutritional counselling and were supplemented with curcumin (Meriva®) for six months. Different parameters were evaluated at baseline and after 3–6 months: uremic toxins, metagenomic of GM, and nutritional, inflammatory, and oxidative status. Curcumin significantly reduced plasma pro-inflammatory mediators (CCL-2, IFN-γ, and IL-4) and lipid peroxidation. Regarding GM, after 6 months of curcumin supplementation, Escherichia-Shigella was significantly lower, while Lachnoclostridium was significant higher. Notably, at family level, Lactobacillaceae spp. were found significantly higher in the last 3 months of supplementation. No adverse events were observed in the supplemented group, confirming the good safety profile of curcumin phytosome after long-term administration.

show abstract

Section: Discussionmentioning

confidence: 79%

Curcumin Supplementation (Meriva®) Modulates Inflammation, Lipid Peroxidation and Gut Microbiota Composition in Chronic Kidney Disease

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Dysbiosis is associated with an increased pro-inflammatory immune response, due to an abnormal proliferation of immune cells and increases the production of pro-inflammatory compounds, such as lipopolysaccharides. 49 Gut dysbiosis furthermore impairs the energy supply to the colonic epithelium and increases epithelial permeability, leading to a “leaky gut.” 50 , 51 In this respect, lyso-Gb 3 increases the biofilm-forming capacity of several individual bacteria, including Bacteroides fragilis . 45 In detail, lyso-Gb 3 also modifies the bacterial composition of the human colon microbiota suspension, increasing bacterial counts of B. fragilis , and modified the formation of short-chain fatty acids, leading to a striking decrease in butyrate concentration.…”

Section: Pathophysiology and Potential Mechanismsmentioning

confidence: 99%

Fabry disease – a multisystemic disease with gastrointestinal manifestations

Lenders

Brand

2022

Gut Microbes

View full text Add to dashboard Cite

Nonspecific gastrointestinal (GI) symptoms, such as postprandial cramping pain, diarrhea, nausea and vomiting are typical symptoms for irritable bowel syndrome or inflammatory bowel disease, but may also be the first symptoms of Fabry disease (FD). This review focus on GI manifestations in FD, by providing an overview of symptoms, a proper diagnosis, an appropriate management by FD-specific and concomitant medications and lifestyle interventions. We provide comprehensive literature-based data combined with personal experience in the management of FD patients. Since FD is rare and the clinical phenotype is heterogeneous, affected patients are often misdiagnosed. Consequently, physicians should consider FD as a possible differential diagnosis when assessing unspecific GI symptoms. Improved diagnostic tools, such as a modified GI symptom assessment scale can facilitate the diagnosis of FD in patients with GI symptoms of unknown cause and thus enable the timely initiation of a disease-specific therapy. Expansive intravenous enzyme replacement therapy with α-galactosidase A or oral chaperone therapy for patients with amenable mutations improve the disease burden including GI symptoms, but a timely start of therapy is crucial for the prognosis. A special diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) or pro- and prebiotics might improve FD-typical GI symptoms. Furthermore, preliminary success was reported with the oral administration of α-galactosidase A. In addition to a timely initiation of FD-specific therapy, affected patients with GI symptoms might benefit from a FODMAP-low diet, pro- and prebiotics and/or low-cost oral substitution with AGAL to support digestion and reduce dysbiosis.

show abstract

“…Intestinal microorganisms can also cause neuroendocrine dysfunction, which can aggravate CKD. Gut dysbiosis impairs the energy supply to the colonic epithelium and increases epithelial permeability, leading to a “leaky gut.” 10,14 Hypertension (HTN) is the most common risk factor of CKD. Gut dysbiosis activates the renin–angiotensin system, leading to HTN and diabetic nephropathy.…”

Section: Mechanism By Which Gut Dysbiosis Influences Ckdmentioning

confidence: 99%

Association between gut dysbiosis and chronic kidney disease: a narrative review of the literature

et al. 2021

View full text Add to dashboard Cite

Chronic kidney disease (CKD) is a serious non-communicable disease that poses a significant burden on healthcare and society. It is essential to devise new strategies to better treat patients with CKD. Research has illustrated that gut dysbiosis, describing an abnormal intestinal ecology, is closely associated with CKD. In this narrative review, we summarized the evidence of their mutual relationship and discussed the potential treatment options to correct gut dysbiosis in patients with CKD. Gut dysbiosis significantly increases the risk of CKD, especially in the older population. Gut dysbiosis also plays a role in CKD complications, such as hypertension, cardiovascular events, and cognitive dysfunction. The relationship between gut dysbiosis and CKD is bidirectional, and CKD itself can lead to changes in gut microecology. The usual therapies for CKD can also increase the incidence of gut dysbiosis. Meanwhile, probiotics and antibiotics are generally used to correct gut dysbiosis. Further studies are required to elaborate the association between gut dysbiosis and CKD, and more treatment options should be explored to prevent CKD in patients with gut dysbiosis.

show abstract

Specific alterations in gut microbiota in patients with chronic kidney disease: an updated systematic review

Cited by 81 publications

References 74 publications

Curcumin Supplementation (Meriva®) Modulates Inflammation, Lipid Peroxidation and Gut Microbiota Composition in Chronic Kidney Disease

Curcumin Supplementation (Meriva®) Modulates Inflammation, Lipid Peroxidation and Gut Microbiota Composition in Chronic Kidney Disease

Fabry disease – a multisystemic disease with gastrointestinal manifestations

Association between gut dysbiosis and chronic kidney disease: a narrative review of the literature

Contact Info

Product

Resources

About